Lockheed Martin: the world’s best defence stock
Lockheed Martin is the industry’s most diversified top-quality company and a robust pick in tough times.
The two parts of the aerospace and defence sector have been affected very differently by Covid-19. Aerospace has suffered badly from the massive reduction in travel. But most of the defence sector has proved resilient.
That makes the few pure-play defence companies in the sector worth investigating. One of the best is Lockheed Martin (NYSE: LMT), supplier of the F-35 fighter and numerous other cutting-edge defence projects.
The global arms race
The geopolitical backdrop is auspicious for Lockheed Martin. Both China and Russia have been actively upgrading their defence forces and the US, the country with the world’s largest defence budget, needs to stay ahead in this arms race. America’s Pacific allies, such as Japan, South Korea, Taiwan and Australia, all depend on a strong American presence in the Asia-Pacific region to temper China’s ambitions.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
China is upgrading its military, has already militarised artificial islands in the South China Sea, threatened Taiwan and its islands with invasion and claimed mineral rights in areas outside its territorial waters. Lockheed is a major supplier to the armed forces of the US and its allies. It is key to maintaining a superior US protective shield in this strategic area.
A widely diversified firm
Lockheed’s largest division is aeronautics (comprising 41% of sales), which includes the fifth-generation F-35 and fourth generation F-16 fighters, P-3 Orion maritime patrol aircraft, C-130 Hercules transport aircrafts and tankers, unmanned aerial vehicles (UAVs) and drones.
Lockheed’s second-largest segment is rotary and mission systems (24% of sales), which includes Sikorsky and Black Hawk helicopters and C6ISR information security systems. (The abbreviation contains six Cs: command, control, communications, computers, cyber-defence and combat systems; the other letters stand for intelligence, surveillance and reconnaissance.)
Lockheed’s space division accounts for 19% of sales. It comprises strategic and missile defence, hypersonic and fleet ballistic missile development, and government or commercial satellite projects, including the Orion deep space exploration craft for Nasa. Finally, there is missiles and fire control (16%), comprising guided multiple-launch rocket systems, anti-ship missiles, hypersonic missile development and Patriot anti-missile systems.
Supplying Britain’s Tridents
This summary illustrates that Lockheed is the world’s highest-quality diversified prime defence contractor. It is a key supplier to both the US and UK governments (Britain buys Lockheed’s Trident submarine-launched missiles and F-35 fighters, for example) and other Western nations.
In 2019 new overseas orders were gained from Singapore, Poland, Canada, Bahrain, Slovakia, Bulgaria and Morocco. Lockheed has large and growing recurring revenues from sustaining the massive F-35 programme, which in 2019 received a US order for 478 F-35s. Major growth drivers include hypersonics, weapons that travel at least five times faster than sound; the Future Vertical Lift programme to develop a new set of military helicopters is another. Within hypersonics, a new missile, the Air-Launched Rapid Response weapon, recently passed its critical design review, which is promising – and important given the Chinese focus on hypersonic development.
Future Vertical Lift encompasses both long range assault and reconnaissance aircraft where the two competitors are Lockheed and Bell Textron. It is likely that the US will give one programme to each company.
Sales and profits on the rise
Lockheed’s 2019 results showed after-tax earnings of $6.23bn on sales of $59.8bn. Sales were up 11.3% over 2018 with earnings up 23.5%. Defence companies receive substantial research and development (R&D) funds from the government to develop major projects.
Lockheed’s own additional 2019 investment in R&D, moreover, was $1.3bn, with $1.5bn going on associated capital expenditure. The order backlog at the of end 2019 was a record $144bn. Earnings per share (EPS) for 2019 rose by 25% while free cash flow came in at $5.83bn. Of this free cash flow, 64% was returned to shareholders via $3.76bn of dividends and $1.2bn of share buybacks.
The results for the first quarter of 2020 showed sales up 9.2% to $15.7bn and after-tax earnings up 0.8% to $1.72bn. Given the uncertain backdrop, it is encouraging that the firm has maintained January’s EPS target for the year: an increase of 7.7%-9.1% while sales are expected to climb by 4.1%-7%. Lockheed has maintained or increased its dividend every year since 2000. The quarterly dividends for 2019 totalled $9.20, up 9.5% from 2018.
The first-quarter news release in late April confirmed a stable order backlog of $144bn. In late May Lockheed announced a new F-35 work schedule agreed with unions to retain all the firm’s skilled workers, but operate a slower workflow because of delays from suppliers. Payments to small and vulnerable suppliers have been accelerated to ensure key suppliers are maintained.
There is some risk that a Democratic president might freeze US defence expenditure, but Joe Biden’s recent anti-China comments make this less likely. The expected 2020 dividend yield is 2.5%, while the stock is on a 2021 price/earnings ratio of 14.5. Analysts at Morningstar estimate the stock’s fair value at $429, 12% above the recent price of $384.
• Dr Mike Tubbs writes on investment, business and technological innovation and has worked in multinationals as head of R&D and in business consultancy and investment management (michael.tubbs@innovatubbs.plus.com)
For decades, Dr Mike Tubbs worked on the 'inside' of corporate giants such as Xerox, Battelle and Lucas. Working in the research and development departments, he learnt what became the key to his investing. Knowledge which gave him a unique perspective on the stock markets.
Dr Tubbs went on to create the R&D Scorecard which was presented annually to the Department of Trade & Industry and the European Commission. It was a guide for European businesses on how to improve prospects using correctly applied research and development.
-
British Airways revamps Avios scheme bringing down flight prices to £1
With the new Avios part-payments scheme you can now bag a British Airways flight for as little as £1
By Oojal Dhanjal Published
-
RBS to close a fifth of branches
Royal Bank of Scotland plans to shut 18 branches across Scotland, resulting in the loss of 105 jobs. We have the full list of closures.
By Ruth Emery Published
-
The industry at the heart of global technology
The semiconductor industry powers key trends such as artificial intelligence, says Rupert Hargreaves
By Rupert Hargreaves Published
-
Three emerging Asian markets to invest in
Professional investor Chetan Sehgal of Templeton Emerging Markets Investment Trust tells us where he’d put his money
By Chetan Sehgal Published
-
What to consider before investing in small-cap indexes
Small-cap index trackers show why your choice of benchmark can make a large difference to long-term returns
By Cris Sholto Heaton Published
-
Why space investments are the way to go for investors
Space investments will change our world beyond recognition, UK investors should take note
By Merryn Somerset Webb Published
-
Time to tap into Africa’s mobile money boom
Favourable demographics have put Africa on the path to growth when it comes to mobile money and digital banking
By Rupert Hargreaves Published
-
M&S is back in fashion: but how long can this success last?
M&S has exceeded expectations in the past few years, but can it keep up the momentum?
By Rupert Hargreaves Published
-
The end of China’s boom
Like the US, China too got fat on fake money. Now, China's doom is not far away.
By Bill Bonner Published
-
Magic mushrooms — an investment boom or doom?
Investing in these promising medical developments might see you embark on the trip of a lifetime.
By Bruce Packard Published